 Lipoproteins, LDL
"Lipoproteins, LDL" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues.
| Descriptor ID |
D008077
|
| MeSH Number(s) |
D10.532.515 D12.776.521.550
|
| Concept/Terms |
Lipoproteins, LDL- Lipoproteins, LDL
- LDL Lipoproteins
- Low-Density Lipoproteins
- Lipoproteins, Low-Density
- Low Density Lipoproteins
- beta-Lipoproteins
- beta Lipoproteins
LDL-1- LDL-1
- LDL1
- Low-Density Lipoprotein 1
- Low Density Lipoprotein 1
- LDL(1)
LDL-2- LDL-2
- LDL2
- Low-Density Lipoprotein 2
- Low Density Lipoprotein 2
- LDL(2)
|
Below are MeSH descriptors whose meaning is more general than "Lipoproteins, LDL".
Below are MeSH descriptors whose meaning is more specific than "Lipoproteins, LDL".
This graph shows the total number of publications written about "Lipoproteins, LDL" by people in UAMS Profiles by year, and whether "Lipoproteins, LDL" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 0 | 2 | 2 | | 2022 | 1 | 1 | 2 | | 2019 | 1 | 0 | 1 | | 2018 | 1 | 3 | 4 | | 2017 | 0 | 1 | 1 | | 2016 | 2 | 3 | 5 | | 2015 | 2 | 1 | 3 | | 2014 | 4 | 0 | 4 | | 2013 | 7 | 2 | 9 | | 2012 | 6 | 1 | 7 | | 2011 | 10 | 3 | 13 | | 2010 | 2 | 2 | 4 | | 2009 | 3 | 0 | 3 | | 2008 | 2 | 1 | 3 | | 2007 | 5 | 2 | 7 | | 2006 | 5 | 2 | 7 | | 2005 | 3 | 4 | 7 | | 2004 | 3 | 4 | 7 | | 2003 | 9 | 5 | 14 | | 2002 | 1 | 0 | 1 | | 2001 | 0 | 1 | 1 | | 2000 | 1 | 1 | 2 | | 1993 | 1 | 0 | 1 | | 1990 | 0 | 1 | 1 | | 1989 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Lipoproteins, LDL" by people in Profiles over the past ten years.
-
Khan MA, Mohammad I, Banerjee S, Tomar A, Varughese KI, Mehta JL, Chandele A, Arockiasamy A. Oxidized LDL receptors: a recent update. Curr Opin Lipidol. 2023 08 01; 34(4):147-155.
-
Vorland CJ, Golzarri-Arroyo L, Maney DL, Brown AW. Determination of sex differences requires formal test for differences: Comment on "lipoprotein-subclass particle numbers in children with abdominal obesity". Pediatr Int. 2023 01; 65(1):e15489.
-
Williams M, Capcha JMC, Irion CI, Seo G, Lambert G, Kamiar A, Yousefi K, Kanashiro-Takeuchi R, Takeuchi L, Saad AG, Mendez A, Webster KA, Goldberger JJ, Hare JM, Shehadeh LA. Mouse Model of Heart Failure With Preserved Ejection Fraction Driven by Hyperlipidemia and Enhanced Cardiac Low-Density Lipoprotein Receptor Expression. J Am Heart Assoc. 2022 09 06; 11(17):e027216.
-
Tomar A, Sahoo S, Aathi M, Kuila S, Khan MA, Ravi GRR, Jeyaraman J, Mehta JL, Varughese KI, Arockiasamy A. Exploring the druggability of oxidized low-density lipoprotein (ox-LDL) receptor, LOX-1, a proatherogenic drug target involved in atherosclerosis. Biochem Biophys Res Commun. 2022 10 01; 623:59-65.
-
Huang SJ, Ma YH, Bi YL, Shen XN, Hou XH, Cao XP, Ou YN, Zhao B, Dong Q, Tan L, Yu JT. Metabolically healthy obesity and lipids may be protective factors for pathological changes of alzheimer's disease in cognitively normal adults. J Neurochem. 2021 05; 157(3):834-845.
-
Kraemer MP, Mao G, Hammill C, Yan B, Li Y, Onono F, Smyth SS, Morris AJ. Effects of diet and hyperlipidemia on levels and distribution of circulating lysophosphatidic acid. J Lipid Res. 2019 11; 60(11):1818-1828.
-
Kattoor AJ, Kanuri SH, Mehta JL. Role of Ox-LDL and LOX-1 in Atherogenesis. Curr Med Chem. 2019; 26(9):1693-1700.
-
Ding Z, Liu S, Wang X, Theus S, Deng X, Fan Y, Zhou S, Mehta JL. PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages. Cardiovasc Res. 2018 07 01; 114(8):1145-1153.
-
Ambrogini E, Que X, Wang S, Yamaguchi F, Weinstein RS, Tsimikas S, Manolagas SC, Witztum JL, Jilka RL. Oxidation-specific epitopes restrain bone formation. Nat Commun. 2018 06 06; 9(1):2193.
-
Jiang ZG, Tapper EB, Kim M, Connelly MA, Krawczyk SA, Yee EU, Herman MA, Mukamal KJ, Lai M. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease. J Clin Gastroenterol. 2018 May/Jun; 52(5):444-451.
-
Dai Y, Wu X, Dai D, Li J, Mehta JL. MicroRNA-98 regulates foam cell formation and lipid accumulation through repression of LOX-1. Redox Biol. 2018 06; 16:255-262.
-
Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL. Oxidative Stress in Atherosclerosis. Curr Atheroscler Rep. 2017 Sep 18; 19(11):42.
-
Bose C, Shah SV, Karaduta OK, Kaushal GP. Carbamylated Low-Density Lipoprotein (cLDL)-Mediated Induction of Autophagy and Its Role in Endothelial Cell Injury. PLoS One. 2016; 11(12):e0165576.
-
Das ND, Yin GN, Choi MJ, Song KM, Park JM, Limanjaya A, Ghatak K, Minh NN, Ock J, Park SH, Kim HM, Ryu JK, Suh JK. Effectiveness of Intracavernous Delivery of Recombinant Human Hepatocyte Growth Factor on Erectile Function in the Streptozotocin-Induced Diabetic Mouse. J Sex Med. 2016 11; 13(11):1618-1628.
-
Ing CT, Zhang G, Dillard A, Yoshimura SR, Hughes C, Palakiko DM, Kehauoha BP, Sinclair KA, Kaholokula JK. Social Support Groups in the Maintenance of Glycemic Control after Community-Based Intervention. J Diabetes Res. 2016; 2016:7913258.
-
Liu Y, Almeida M, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL. Skeletal inflammation and attenuation of Wnt signaling, Wnt ligand expression, and bone formation in atherosclerotic ApoE-null mice. Am J Physiol Endocrinol Metab. 2016 May 01; 310(9):E762-73.
-
Dai Y, Zhang Z, Cao Y, Mehta JL, Li J. MiR-590-5p Inhibits Oxidized- LDL Induced Angiogenesis by Targeting LOX-1. Sci Rep. 2016 Mar 02; 6:22607.
-
Thakkar S, Wang X, Khaidakov M, Dai Y, Gokulan K, Mehta JL, Varughese KI. Structure-based Design Targeted at LOX-1, a Receptor for Oxidized Low-Density Lipoprotein. Sci Rep. 2015 Nov 18; 5:16740.
-
Wang X, Ding Z, Lin J, Guo Z, Mehta JL. LOX-1 in macrophage migration in response to ox-LDL and the involvement of calpains. Biochem Biophys Res Commun. 2015 Nov 06; 467(1):135-9.
-
Ding Z, Liu S, Wang X, Deng X, Fan Y, Shahanawaz J, Shmookler Reis RJ, Varughese KI, Sawamura T, Mehta JL. Cross-talk between LOX-1 and PCSK9 in vascular tissues. Cardiovasc Res. 2015 Sep 01; 107(4):556-67.
-
Reschen ME, Gaulton KJ, Lin D, Soilleux EJ, Morris AJ, Smyth SS, O'Callaghan CA. Lipid-induced epigenomic changes in human macrophages identify a coronary artery disease-associated variant that regulates PPAP2B Expression through Altered C/EBP-beta binding. PLoS Genet. 2015 Apr; 11(4):e1005061.
-
Dai Y, Dai D, Wang X, Ding Z, Li C, Mehta JL. GLP-1 agonists inhibit ox-LDL uptake in macrophages by activating protein kinase A. J Cardiovasc Pharmacol. 2014 Jul; 64(1):47-52.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|